Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Sales | 8,092,000 | 7,310,000 | 7,222,000 | 7,639,000 | 7,843,000 |
| Cost of Goods | 2,636,000 | 2,310,000 | 2,391,000 | 2,558,000 | 2,652,000 |
| Gross Profit | 5,456,000 | 5,000,000 | 4,831,000 | 5,081,000 | 5,191,000 |
| Operating Expenses | 3,546,000 | 3,309,000 | 3,162,000 | 2,595,000 | 3,314,000 |
| Operating Income | 1,910,000 | 1,691,000 | 1,669,000 | 2,486,000 | 1,877,000 |
| Interest Expense | 233,000 | 194,000 | 162,000 | 156,000 | 194,000 |
| Other Income | 28,000 | -883,000 | -400,000 | -1,888,000 | 28,000 |
| Pre-tax Income | 1,705,000 | 614,000 | 1,107,000 | 442,000 | 1,711,000 |
| Income Tax | 193,000 | 139,000 | 348,000 | 805,000 | 316,000 |
| Net Income Continuous | 1,512,000 | 475,000 | 759,000 | -363,000 | 1,395,000 |
| Minority Interests | -94,000 | -34,000 | -210,000 | -183,000 | -183,000 |
| Net Income | $1,418,000 | $441,000 | $549,000 | $-546,000 | $1,212,000 |
| EPS Basic Total Ops | 0.36 | 0.11 | 0.14 | -0.14 | 0.31 |
| EPS Basic Continuous Ops | 0.36 | 0.11 | 0.14 | -0.14 | 0.31 |
| EPS Diluted Total Ops | 0.36 | 0.11 | 0.14 | -0.14 | 0.31 |
| EPS Diluted Continuous Ops | 0.36 | 0.11 | 0.14 | -0.14 | 0.31 |
| EBITDA(a) | $2,434,000 | $1,003,000 | $1,747,000 | $598,000 | $2,589,000 |